SEC 13F Intelligence

Managers / Q2 2020 · view latest →

ARCH Venture Management, LLC

CIK 0001274403 · C/O ARCH VENTURE PARTNERS, 8755 W. HIGGINS RD. #1025, CHICAGO, IL, 60631 · 7733806600

Reported Value
$30M
Q2 2020
Positions
4
Filings on Record
28
2019–present window
Filed
Aug 12, 2020
original filing

Summary

Arch Venture Management, LLC reported $30M in U.S.-listed holdings across 4 positions for Q2 2020.

The portfolio is heavily concentrated: RUBYUSD alone accounts for 52.7% of reported value.

Compared with Q1 2020, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
+13.7%
vs prior filed quarter
Largest Position
+52.7%
Rubius Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $99MQ4 ’18Q1 ’19: $104MQ2 ’19: $97MQ3 ’19: $91MQ4 ’19: $77MQ4 ’19Q1 ’20: $59MQ2 ’20: $30MQ3 ’20: $20MQ4 ’21: $945MQ4 ’21Q1 ’22: $700MQ2 ’22: $821MQ3 ’22: $771MQ4 ’22: $390MQ4 ’22Q1 ’23: $207MQ2 ’23: $162MQ3 ’23: $154MQ4 ’23: $164MQ4 ’23Q1 ’24: $80MQ2 ’24: $266MQ3 ’24: $261MQ4 ’24: $230MQ4 ’24Q1 ’25: $206MQ2 ’25: $299MQ3 ’25: $492MQ4 ’25: $652MQ4 ’25Q1 ’26: $677Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 100.0%
  • Common Stock · 100.0% · $30M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IOTSEURADESTO TECHNOLOGIES CORPSOLD OUT−1.88M0−$21M$0
SYRSEURSYROS PHARMACEUTICALS INCTRIMMED−2.66M400.0K−$14M$4M
KURAKURA ONCOLOGY INCTRIMMED−200.0K206.3K−$680,000$3M
RUBYUSDRUBIUS THERAPEUTICS INCHELD+02.62M+$4M$16M
CHMACHIASMA INCHELD+01.20M+$2M$6M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2020

4 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1RUBYUSDRUBIUS THERAPEUTICS INChistory →COM52.68%$16M2.62M
2CHMACHIASMA INChistory →COM21.66%$6M1.20M
3SYRSEURSYROS PHARMACEUTICALS INChistory →COM14.35%$4M400.0K
4KURAKURA ONCOLOGY INChistory →COM11.31%$3M206.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$677M10May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$652M9Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$492M9Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$299M11Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$206M9May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$230M9Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$261M9Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$266M9Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$80M8May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$164M7Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$154M7Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$162M6Aug 9, 202313F-HRchanges · EDGAR ↗
Q1 2023$207M8May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$390M8Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$771M10Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$821M10Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$700M8May 27, 2022RESTATEMENTchanges · EDGAR ↗
Q4 2021$945M9Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2020$20M3Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$30M4Aug 12, 202013F-HRchanges · EDGAR ↗
Q1 2020$59M5May 6, 202013F-HRchanges · EDGAR ↗
Q4 2019$77M5Feb 5, 202013F-HRchanges · EDGAR ↗
Q3 2019$91M5Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$97M4Aug 9, 201913F-HRchanges · EDGAR ↗
Q1 2019REVEALED$104M7May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$99M5Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.